Project Grant R01HL187953
Award Date 8/1/26
Completion Date 4/30/30
Dollars Obligated $775K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Utica, NY 13501, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), part of the Department of Health and Human Services National Institutes of Health, awarded The Medical College of Wisconsin, Inc. $792,011 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to validate plasma cell-free DNA (CFDNA)—including nuclear and mitochondrial variants—as a clinically actionable biomarker for predicting critical post-surgical events in infants undergoing complex congenital heart surgery....
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart, Lung, and Blood Institute, part of the National Institutes of Health under the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc., $234,000 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The Medical College of Wisconsin will conduct a single-cell dissection of cellular and transcriptional dynamics driving post-transplant relapse in myelodysplastic syndromes (MDS). The research leverages longitudinal...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia Research Institute $889,804 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds investigation of MED12 as a novel regulator of vasculogenesis using a MED12-deficient, KDRL.mCherry transgenic zebrafish model that permits direct visualization of developing vasculature via fluorescent microscopy and isolation of vascular endothelial cells through...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the regulation of ribosomal RNA transcription by MYC in hematopoiesis. The funded research dissects how MYC, a developmental transcription factor often dysregulated in disease, directly regulates ribosomal RNA (rRNA) transcription by RNA polymerase I in hematopoietic cells. The work addresses a...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $581,307 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mutation-specific responses to myosin inhibitors in human iPSC models of hypertrophic cardiomyopathy. The research evaluates how different HCM-causing mutations in genes encoding cardiac sarcomeric proteins respond to mavacamten, a myosin ATPase inhibitor approved to treat obstructive HCM....
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...